Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, et al. Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. BMC Cancer 2022;22:1348.
PMID: 36550442